Many companies are beginning to bring their cardiovascular franchises together into a holistic, cross-therapy cardiovascular portfolio by seeking new indications for existing drugs, combining cross-risk factor therapies and branching out to cover all aspects of cardiovascular disease. The purpose of this brief is to offer an overview of recent events in the cardiovascular market, as well as an insight into their implications for the future. This brief identifies the best and fastest selling products and major players in therapy areas as well as in the market overall. It also provides details of company news and R&D developments that will shape the market in the future.
